Drug repurposing for COVID-19: could vitamin C combined with glycyrrhizic acid be at play by the findings of Li et al.'s database-based network pharmacology analysis?. Issue 2 (1st December 2020)

• Record Type: Journal Article
• Authors: Huang, Yu-Xi; Wang, Wen-Xiao; Tang, Yu-Ping; Yue, Shi-Jun
• Is Part Of: Briefings in bioinformatics. Volume 22:Issue 2(2021)
• Page Start: 1508
• Page End: 1510
• Publication Date: 2020-12-01
• Subjects: COVID-19 -- vitamin C -- glycyrrhizic acid -- network pharmacology; Genetics -- Data processing -- Periodicals; Molecular biology -- Data processing -- Periodicals; Genomes -- Data processing -- Periodicals; 572.80285
• DOI: 10.1093/bib/bbaa330
• Languages: English
• ISSNs: 1467-5463

Abstract

Abstract: The outbreak and pandemic of SARS-CoV-2 in 2019 has caused a severe public health burden and will challenge global health for the future. The discovery and mechanistic investigation of drugs against Coronavirus disease 2019 (COVID-19) is in deadly demand. The paper published by Li and colleagues proposed the hypothesis that vitamin C combined with glycyrrhizic acid in treating COVID-19 and its mechanistic investigation was performed by a database-based network pharmacology. In this letter, we present critical comments on the limitations and insufficiencies involved, from both the perspective of network pharmacology and current evidence on COVID-19.